These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. Patient age and cancer treatment decisions. Patient and physician views. Kutner JS; Vu KO; Prindiville SA; Byers TE Cancer Pract; 2000; 8(3):114-9. PubMed ID: 11898135 [TBL] [Abstract][Full Text] [Related]
6. Impact of patient age and comorbidity on surgeon versus oncologist preferences for adjuvant chemotherapy for stage III colon cancer. Krzyzanowska MK; Regan MM; Powell M; Earle CC; Weeks JC J Am Coll Surg; 2009 Feb; 208(2):202-9. PubMed ID: 19228531 [TBL] [Abstract][Full Text] [Related]
7. Quality of life as subjective experience: reframing of perception in patients with colon cancer undergoing radical resection with or without adjuvant chemotherapy. Swiss Group for Clinical Cancer Research (SAKK). Bernhard J; Hürny C; Maibach R; Herrmann R; Laffer U Ann Oncol; 1999 Jul; 10(7):775-82. PubMed ID: 10470423 [TBL] [Abstract][Full Text] [Related]
8. Decision-making under clinical uncertainty: An in-depth examination of provider perspectives on adjuvant chemotherapy for stage II colon cancer. Shelton RC; Brotzman LE; Crookes DM; Robles P; Neugut AI Patient Educ Couns; 2019 Feb; 102(2):284-290. PubMed ID: 30262401 [TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy for stage III colon cancer: do physicians agree about the importance of patient age and comorbidity? Keating NL; Landrum MB; Klabunde CN; Fletcher RH; Rogers SO; Doucette WR; Tisnado D; Clauser S; Kahn KL J Clin Oncol; 2008 May; 26(15):2532-7. PubMed ID: 18487570 [TBL] [Abstract][Full Text] [Related]
10. Deciding on adjuvant chemotherapy for elderly patients with stage III colon cancer: a qualitative insight into the perspectives of surgeons and medical oncologists. van Erning FN; Janssen-Heijnen ML; Creemers GJ; Pruijt HF; Maas HA; Lemmens VE J Geriatr Oncol; 2015 May; 6(3):219-24. PubMed ID: 25703856 [TBL] [Abstract][Full Text] [Related]
11. Adjuvant hyperthermic intraperitoneal chemotherapy in patients with locally advanced colon cancer (COLOPEC): a multicentre, open-label, randomised trial. Klaver CEL; Wisselink DD; Punt CJA; Snaebjornsson P; Crezee J; Aalbers AGJ; Brandt A; Bremers AJA; Burger JWA; Fabry HFJ; Ferenschild F; Festen S; van Grevenstein WMU; Hemmer PHJ; de Hingh IHJT; Kok NFM; Musters GD; Schoonderwoerd L; Tuynman JB; van de Ven AWH; van Westreenen HL; Wiezer MJ; Zimmerman DDE; van Zweeden AA; Dijkgraaf MGW; Tanis PJ; Lancet Gastroenterol Hepatol; 2019 Oct; 4(10):761-770. PubMed ID: 31371228 [TBL] [Abstract][Full Text] [Related]
12. Differences in the outcomes of adjuvant chemotherapy for colon cancer prescribed by physicians in different disciplines: a population-based study in Taiwan. Hsieh CI; Kuo RN; Liang CC; Tsai HY; Chung KP BMJ Open; 2018 Dec; 8(12):e021341. PubMed ID: 30567819 [TBL] [Abstract][Full Text] [Related]
13. Are patients and physicians willing to accept less-radical procedures for cervical cancer? Gungorduk K; Kocian R; Basaran D; Turan T; Ozdemir A; Cibula D J Gynecol Oncol; 2018 Jul; 29(4):e50. PubMed ID: 29770621 [TBL] [Abstract][Full Text] [Related]
14. Reasons physicians do not recommend and patients refuse adjuvant chemotherapy for stage III colon cancer: a population based chart review. El Shayeb M; Scarfe A; Yasui Y; Winget M BMC Res Notes; 2012 Jun; 5():269. PubMed ID: 22676354 [TBL] [Abstract][Full Text] [Related]
15. Circulating Tumor DNA Analyses as Markers of Recurrence Risk and Benefit of Adjuvant Therapy for Stage III Colon Cancer. Tie J; Cohen JD; Wang Y; Christie M; Simons K; Lee M; Wong R; Kosmider S; Ananda S; McKendrick J; Lee B; Cho JH; Faragher I; Jones IT; Ptak J; Schaeffer MJ; Silliman N; Dobbyn L; Li L; Tomasetti C; Papadopoulos N; Kinzler KW; Vogelstein B; Gibbs P JAMA Oncol; 2019 Dec; 5(12):1710-1717. PubMed ID: 31621801 [TBL] [Abstract][Full Text] [Related]
16. Discordant attitudes and beliefs about cancer clinical trial participation between physicians, research staff, and cancer patients. Hillyer GC; Beauchemin M; Hershman DL; Kelsen M; Brogan FL; Sandoval R; Schmitt KM; Reyes A; Terry MB; Lassman AB; Schwartz GK Clin Trials; 2020 Apr; 17(2):184-194. PubMed ID: 32009456 [TBL] [Abstract][Full Text] [Related]
17. Willingness to accept chemotherapy and attitudes towards costs of cancer treatment; A multisite survey study in the Netherlands. van Dijk EF; Coşkuntürk M; Zuur AT; van der Palen J; van der Graaf WT; Timmer-Bonte JN; Wymenga AN Neth J Med; 2016 Aug; 74(7):292-300. PubMed ID: 27571944 [TBL] [Abstract][Full Text] [Related]
18. Patients' Preferences for 3 Months vs 6 Months of Adjuvant Chemotherapy for Colon Cancer. Blinman P; Martin A; Jefford M; Goldstein D; Boadle D; Morris M; Tebbutt N; Aiken C; Harkin A; Segelov E; Haydon A; Iveson T; Stockler MR JNCI Cancer Spectr; 2021 Feb; 5(1):. PubMed ID: 34159294 [TBL] [Abstract][Full Text] [Related]
19. Current status on microsatellite instability, prognosis and adjuvant therapy in colon cancer: A nationwide survey of medical oncologists, colorectal surgeons and gastrointestinal pathologists. Toh JWT; Mahajan H; Chapuis P; Spring K Cancer Rep (Hoboken); 2021 Feb; 4(1):e1297. PubMed ID: 33030308 [TBL] [Abstract][Full Text] [Related]
20. Physician preferences and attitudes regarding different models of cancer survivorship care: a comparison of primary care providers and oncologists. Cheung WY; Aziz N; Noone AM; Rowland JH; Potosky AL; Ayanian JZ; Virgo KS; Ganz PA; Stefanek M; Earle CC J Cancer Surviv; 2013 Sep; 7(3):343-54. PubMed ID: 23526165 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]